Boston Scientific/ASTI deal targets bifurcated vessels
This article was originally published in The Gray Sheet
Executive Summary
Purchase of Advanced Stent Technologies, Inc. Dec. 16 will allow Boston Scientific to combine its Taxus paclitaxel-eluting stent technology with ASTI's Petal bifurcation coronary stent design to treat disease in bifurcated vessels, Boston Scientific says. Bifurcated lesions are present in as many as 30% of diseased vessels. A bare-metal Petal has FDA trial go-ahead (1"The Gray Sheet" Sept. 13, 2004, In Brief)...
You may also be interested in...
AST’s blossoming stent trial
Advanced Stent Technologies expects to receive FDA approval to begin enrollment "in the next several months" of up to 100 patients at four to six U.S. sites to study its Petal coronary bifurcation bare-metal stent. The firm received conditional approval for use of Petal and its delivery system in 30 nonrandomized patients in its U.S. BOSS study on Sept. 3. FDA had cleared an investigational device exemption for Petal in December 2001 for a 30-patient feasibility study (1"The Gray Sheet" Sept. 3, 2004, p. 27). AST gained a CE mark for a rapid-exchange version of its SLK-View DSX stent for treating bifurcated lesions in February 2003...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.